Olivia Couch
Psychiatric/Mental Health · Anniston, ALNPI 1598209330
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 336 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations.
Across 336 payments — averaging $18.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Teva Pharmaceuticals USA, Inc.$543
- Neurocrine Biosciences, Inc.$539
- Otsuka America Pharmaceutical, Inc.$450
- Alkermes, Inc.$398
- plus $2K from 19 others
What the payments were for
- Food & beverage$6,331100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 96 | $1,194 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 56 | $1,038 |
| Teva Pharmaceuticals USA, Inc. | 31 | $543 |
| Neurocrine Biosciences, Inc. | 15 | $539 |
| Otsuka America Pharmaceutical, Inc. | 24 | $450 |
| Alkermes, Inc. | 16 | $398 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $377 |
| Vanda Pharmaceuticals Inc. | 12 | $302 |
| Johnson & Johnson | 11 | $247 |
| Lundbeck LLC | 12 | $228 |
| Axsome Therapeutics, Inc. | 2 | $150 |
| Corium, LLC | 7 | $145 |
| Sunovion Pharmaceuticals Inc. | 6 | $136 |
| Avanir Pharmaceuticals, Inc. | 6 | $124 |
| Almatica Pharma LLC | 5 | $94 |
| Bausch Health US, LLC | 4 | $73 |
| E.r. Squibb & Sons, L.L.C. | 3 | $73 |
| Ironshore Pharmaceuticals Inc. | 3 | $54 |
| Tris Pharma Inc | 2 | $42 |
| Eisai Inc. | 2 | $31 |
| Harmony Biosciences LLC | 1 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Merck | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,331 in reported general payments places this provider in the 85th percentile of 378 psychiatric/mental health providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 13 | $209,848 |
| RexultiBrexpiprazole | 15 | $29,013 |
| VraylarCariprazine Hcl | 12 | $17,596 |
| TrintellixVortioxetine Hydrobromide | 14 | $16,799 |
| Lurasidone Hcl | 43 | $11,175 |
| Oxcarbazepine | 22 | $2,259 |
| Divalproex Sodium ErDivalproex Sodium | 55 | $1,649 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 23 | $1,551 |
| Buspirone Hcl | 64 | $1,486 |
| Aripiprazole | 28 | $1,300 |
| Prazosin Hcl | 46 | $1,295 |
| Doxepin Hcl | 29 | $1,147 |
| Quetiapine Fumarate | 51 | $1,106 |
| Lamotrigine | 68 | $787 |
| Carbamazepine | 17 | $551 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $543 | $209,84813 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $450 | $29,01315 claims |
| AbbVieVraylar | $1,194 | $17,59612 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $377 | $16,79914 claims |
| Almatica Pharma LLCSertraline Hcl | $94 | $26524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 378 psychiatric/mental health providers in Alabama.
Other psychiatric/mental health in Anniston
- Christian ArringtonAnniston$11K
- Laura GrahamMontgomery$80K
- Yuliya SpencerBirmingham$65K
- Keri BarrBay Minette$35K
- John HayesMobile$30K
- Logan ThrasherHoover$22K
- Anthony PhillipsHelena$15K
- Ian KinzerHuntsville$15K
- Latisha AliHoover$15K
- Taylor BarrettGadsden$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.